Team Members

---

I obtained my PhD from the University of British Columbia under the supervision of Professor Marcel Bally, developing lipid membrane nanoparticle delivery systems which founded my interest in cancer therapeutics, lipid bilayer chemistry and nano-based structures. My PhD thesis and first 1st authored publication served as the basis of my inventorship toward the development of the FDA approved (2017) liposomal formulation Vyxeos. Completed clinical trials demonstrate that Vyxeos treatment doubles the overall median survival rate and reduces the risk of death by 31% for patients with Acute Myeloid Leukaemia.  After my Ph.D., I carried out a doctoral fellowship in cellular biology supported by the Natural Science and Engineering Research Council (NSERC) with Professor Paul Lehner at the University of Cambridge studying RING ubiquitin E3 ligases that regulate immune receptors. I completed a second post doctorate with Professor Tessa Holyoake, funded by Bloodwise that involved investigating critical pathways in Chronic Myeloid Leukaemia.